Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Aug 3, 2015 at 11:25 AM EDT

Independent Research Firm Sees Higher Upside in Amgen

According to Argus, second-quarter earnings, along with a strong pipeline and general outlook, have positioned Amgen to take the market…

Chris Lange | Aug 3, 2015 at 11:05 AM EDT

Positive Developments Around Ebola

Ebola fears have subsided and the development of a vaccine or related drugs has been put on the back burner…

Lee Jackson | Aug 3, 2015 at 10:40 AM EDT

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving…

Chris Lange | Aug 3, 2015 at 10:15 AM EDT

INC Research Files for Secondary Offering

INC Research Holdings has filed with the Securities and Exchange Commission (SEC) for a secondary offering.

Chris Lange | Aug 3, 2015 at 10:05 AM EDT

Zynerba Updates IPO Terms

Zynerba Pharmaceuticals has amended its filing with the Securities and Exchange Commission (SEC) for its initial public offering

Jon C. Ogg | Jul 31, 2015 at 1:44 PM EDT

Teva Proves Its Decade-Hold Status With Massive Funding

ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday…

Chris Lange | Jul 31, 2015 at 10:10 AM EDT

Global Blood Therapeutics Updates Terms in IPO

ThinkstockGlobal Blood Therapeutics Inc. filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial…

Paul Ausick | Jul 30, 2015 at 4:26 PM EDT

Amgen Earnings Point to New 52-Week High

ThinkstockAmgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm…

Chris Lange | Jul 30, 2015 at 3:52 PM EDT

Why Merrill Lynch Upgraded Aetna

ThinkstockMerrill Lynch upgraded Aetna Inc. (NYSE: AET) to Buy from Neutral but maintains its price objective at $132, implying an…

Chris Lange | Jul 30, 2015 at 11:23 AM EDT

What to Expect from Amgen Earnings

ThinkstockAmgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates…

Chris Lange | Jul 30, 2015 at 9:13 AM EDT

Are Teva Earnings Enough?

ThinkstockTeva Pharmaceutical Industries Limited (NYSE: TEVA) reported its second-quarter financial results Thursday before the markets opened. The company had $1.43…

Douglas A. McIntyre | Jul 30, 2015 at 5:48 AM EDT

More Doctors Flee Private Practice

ThinkstockThe old style independent doctor has continued to disappear. Practicing in a hospital has become a better financial deal, as…

Chris Lange | Jul 29, 2015 at 5:09 PM EDT

Is This a Turning Point For Unilife?

ThinkstockUnilife Corp. (NASDAQ: UNIS) announced the introduction of the Imperium platform of instant patch pumps for insulin. The platform is…

Chris Lange | Jul 29, 2015 at 1:27 PM EDT

Should Gilead Really Be Rated Underperform?

ThinkstockMost analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis…

Chris Lange | Jul 29, 2015 at 12:09 PM EDT

Who Really Won in the PDL and Ariad Royalty Deal?

ThinkstockThe solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and…

1 … 252 253 254 255 256 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Independent Research Firm Sees Higher Upside in Amgen

Positive Developments Around Ebola

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

INC Research Files for Secondary Offering

Zynerba Updates IPO Terms

Teva Proves Its Decade-Hold Status With Massive Funding

Global Blood Therapeutics Updates Terms in IPO

Amgen Earnings Point to New 52-Week High

Why Merrill Lynch Upgraded Aetna

What to Expect from Amgen Earnings

Are Teva Earnings Enough?

More Doctors Flee Private Practice

Is This a Turning Point For Unilife?

Should Gilead Really Be Rated Underperform?

Who Really Won in the PDL and Ariad Royalty Deal?

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Independent Research Firm Sees Higher Upside in Amgen

Positive Developments Around Ebola

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

INC Research Files for Secondary Offering

Zynerba Updates IPO Terms

Teva Proves Its Decade-Hold Status With Massive Funding

Global Blood Therapeutics Updates Terms in IPO

Amgen Earnings Point to New 52-Week High

Why Merrill Lynch Upgraded Aetna

What to Expect from Amgen Earnings

Are Teva Earnings Enough?

More Doctors Flee Private Practice

Is This a Turning Point For Unilife?

Should Gilead Really Be Rated Underperform?

Who Really Won in the PDL and Ariad Royalty Deal?

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how